Literature DB >> 2822556

Agonist/antagonist activity of ergocristine at alpha-adrenoceptors in the rat.

J Roquebert1, P Demichel.   

Abstract

(1) The action of ergocristine at alpha-adrenoceptors was studied in vivo in the pithed rat, and in vitro on the rat isolated vas deferens. (2) In the pithed rat, the pressor response to ergocristine was reduced competitively by yohimbine, but not by prazosin. (3) Ergocristine decreased the tachycardia elicited by electrical stimulation of the cardioaccelerator sympathetic nerves, this effect being antagonized by yohimbine. (4) At postsynaptic alpha 1-adrenoceptors, on the vas deferens of the rat, ergocristine antagonized the contraction induced by phenylephrine in a competitive manner (pA2 = 7.85). (5) These results show that vasoconstriction due to ergocristine is mediated by alpha 2-adrenoceptors and that, in the rat, ergocristine acts as an alpha 2-adrenoceptors agonist, and an alpha 1-adrenoceptors antagonist.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2822556     DOI: 10.1111/j.1472-8206.1987.tb00542.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  3 in total

1.  Pharmacological properties of a wide array of ergolines at functional alpha(1)-adrenoceptor subtypes.

Authors:  Tilo Görnemann; Sven Jähnichen; Björn Schurad; Klaus Peter Latté; Reinhard Horowski; Johannes Tack; Miroslav Flieger; Heinz H Pertz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-08       Impact factor: 3.000

2.  A comparative study of topical natural ergot alkaloids on the intraocular pressure and aqueous humor dynamics in oclular normotensive and alpha-chymotrypsin-induced ocular hypertensive rabbits.

Authors:  Gustavo Puras; Juan Santafé; José Segarra; Manuel Garrido; José Melena
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-05-16       Impact factor: 3.117

3.  Vasoactive Effects of Acute Ergot Exposure in Sheep.

Authors:  Rossalin Yonpiam; Jair Gobbet; Ashok Jadhav; Kaushik Desai; Barry Blakley; Ahmad Al-Dissi
Journal:  Toxins (Basel)       Date:  2021-04-20       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.